CRISPR Gene-Editing Therapies Make Strides, but Cost and Accessibility Remain Key Challenges
Updated: Oct 5
As CRISPR-based therapies edge closer to becoming mainstream, groundbreaking treatments for blood disorders and cancer are making their mark. One of the most exciting developments is Casgevy, a gene-editing therapy that has shown remarkable success in treating sickle-cell disease and β-thalassaemia. Approved in both the UK and US, Casgevy works by reactivating fetal hemoglobin, offering patients a chance at long-term relief with fewer blood transfusions and hospital visits. With benefits lasting at least five years, this treatment is a game-changer.
Despite the promising results, Casgevy's biggest problem is its hefty price tag of $2.2 million per patient, which raises questions about accessibility. Harvesting and editing a patient’s stem cells, an essential step in this treatment, can take months. Many countries are still wrestling with how to integrate such a costly therapy into their healthcare systems. The tension between revolutionary science and the realities of healthcare budgets continues to rise.
The concerns do not stop there. For treatments like Casgevy, chemotherapy is required to prepare patients' bodies for the edited stem cells. This chemotherapy, typically using a drug called busulfan, is necessary to eradicate the patient’s existing blood stem cells, creating space for the edited cells to thrive. While it is essential for the success of the therapy, this step can cause serious side effects, including infertility. Researchers are working on ways to reduce these risks such as exploring alternatives like targeted antibodies.
One of the strategies to improve both safety and effectiveness is to develop more precise editing methods. For instance, Beam Therapeutics is taking things a step further with base editing, a more precise method that is already showing impressive results in early clinical trials for sickle-cell disease. Prime Medicine is working on even more refined techniques with prime editing, aiming to make gene therapies safer and more versatile. These innovations could be the key to making gene-editing treatments more affordable and widely accessible in the future.
Despite the numerous challenges, each breakthrough in CRISPR technology brings us closer to making CRISPR therapies safer and more accessible.
Created: Dec 19th, 2024
Citations:
GEN. (2024). Gene therapy reverses effects of heart failure and restores heart function in minipigs. Genetic Engineering & Biotechnology News. Retrieved from https://www.genengnews.com/topics/translational-medicine/gene-therapy-reverses-effects-of-heart-failure-and-restores-heart-function-in-minipigs/
Keep exploring with Gene Tech Times
Free guide: subscribe to the Gene Tech Times Briefing on our homepage and get Every FDA-Approved Gene Therapy at a Glance in your inbox.
Watch: 30-second gene therapy Shorts on Gene Tech Times Academy.
Read: The Cheat Codes of Our Genes, real stories of mutations that make some people immune to disease.
New to gene therapy? Start with The Life-Changing Power of Gene Therapy.
As an Amazon Associate, Gene Tech Times earns from qualifying purchases.
Comments